التداخل بين بيكلوميثازون وأوميكليدينيوم وفيلانتيرول

• use of a long-acting beta 2 -adrenergic agonist (LABA), including vilanterol, one of the active ingredients in Umeclidinium and Vilanterol ELLIPTA, without an inhaled corticosteroid (ICS), in patients with asthma [see Warnings and Precautions ( 5.1 )] .

• Use of a LABA, including Umeclidinium and Vilanterol ELLIPTA, without an inhaled corticosteroid is contraindicated in patients with asthma.

• LABA monotherapy (without an inhaled corticosteroid) for asthma increases the risk of serious asthma-related events.

Treat bronchospasm immediately with inhaled, short-acting bronchodilator and discontinue QVAR REDIHALER.

Instruct patients to contact their physician immediately if episodes of asthma that are not responsive to bronchodilators occur during the course of treatment with QVAR REDIHALER.

If inhalation induced bronchospasm occurs following dosing with QVAR REDIHALER, it should be treated immediately with an inhaled, short‑acting bronchodilator.